ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
gavros
|
247 |
58K |
3 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
247
|
58K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
gavros
|
247 |
58K |
7 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
247
|
58K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
10 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
22 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
22
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
10 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
gavros
|
282 |
73K |
2 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
282
|
73K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
11 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
2 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
1 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
4 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
gavros
|
100 |
26K |
7 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
100
|
26K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
gavros
|
100 |
26K |
2 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
100
|
26K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
gavros
|
100 |
26K |
5 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
100
|
26K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
gavros
|
100 |
26K |
1 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
100
|
26K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
gavros
|
77 |
18K |
11 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
18K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
6 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.2K
|
302K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
gavros
|
33 |
8.4K |
16 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
33
|
8.4K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
gavros
|
126 |
31K |
13 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
126
|
31K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
gavros
|
126 |
31K |
3 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
126
|
31K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
gavros
|
126 |
31K |
5 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
126
|
31K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
share dumping
|
|
gavros
|
17 |
4.1K |
6 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
17
|
4.1K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
1.2K
|
302K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
13 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.2K
|
302K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
5 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.2K
|
302K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
7 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
1.2K
|
302K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
gavros
|
311 |
77K |
25 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
311
|
77K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Top 200 PAAO holders as at 29 Feb 2024
|
|
gavros
|
35 |
7.8K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
35
|
7.8K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
5 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
gavros
|
152 |
45K |
21 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
gavros
|
209 |
49K |
27 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
209
|
49K
|
27
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
21 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
21
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
gavros
|
14 |
8.8K |
1 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
14
|
8.8K
|
1
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
gavros
|
14 |
8.8K |
1 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
14
|
8.8K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
13 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
9 |
11/02/24 |
11/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
7 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
gavros
|
1.2K |
302K |
9 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
1.2K
|
302K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
gavros
|
430 |
106K |
15 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
430
|
106K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
gavros
|
430 |
106K |
16 |
12/01/24 |
12/01/24 |
ASX - By Stock
|
430
|
106K
|
16
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Up to 0.9% Li2O in First-Pass Paynes Find Rock Chips
|
|
gavros
|
31 |
19K |
1 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
31
|
19K
|
1
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Up to 0.9% Li2O in First-Pass Paynes Find Rock Chips
|
|
gavros
|
31 |
19K |
0 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
31
|
19K
|
0
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Up to 0.9% Li2O in First-Pass Paynes Find Rock Chips
|
|
gavros
|
31 |
19K |
1 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
31
|
19K
|
1
|
|
ASX - By Stock
|
GSM |
Re:
Ann: Up to 0.9% Li2O in First-Pass Paynes Find Rock Chips
|
|
gavros
|
31 |
19K |
1 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
31
|
19K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
gavros
|
430 |
106K |
11 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
430
|
106K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FightMND Invites PharmAust to Apply for Phase 2/3 Funding
|
|
gavros
|
56 |
15K |
7 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
56
|
15K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FightMND Invites PharmAust to Apply for Phase 2/3 Funding
|
|
gavros
|
56 |
15K |
3 |
26/12/23 |
26/12/23 |
ASX - By Stock
|
56
|
15K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
gavros
|
43 |
11K |
2 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
43
|
11K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Launches Interactive Investor Hub
|
|
gavros
|
16 |
3.2K |
8 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
16
|
3.2K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Launches Interactive Investor Hub
|
|
gavros
|
16 |
3.2K |
4 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
16
|
3.2K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Raises $3.5 Million at a Premium
|
|
gavros
|
60 |
14K |
13 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
60
|
14K
|
13
|
|